[May 22, 2013]

Research and Markets: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - EU Analysis and Market Forecasts

Research and Markets (http://www.researchandmarkets.com/research/tfgdmk/medipoint) has announced the addition of the "MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - EU Analysis and Market Forecasts" report to their offering.

In Europe, the ACS (News - Alert) in vitro diagnostics market is dominated by a single biomarker test, cardiac troponins. However, this market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, the emergence of pipeline biomarker tests will change the landscape of ACS in vitro diagnostic testing and is expected to provide enhancements in the early diagnosis of the disease.

Acute coronary syndrome (ACS) consists of two major diseases, myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and Europea countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. The ACS diagnostic cardiac biomarker reagents market is dominated by the cardiac troponins, the gold-standard biomarkers for the diagnosis of MI.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview 3.1 Acute Coronary Syndromes 3.2 Anatomy and Physiology 3.3 Pathophysiology 3.4 Clinical Presentation 3.5 Clinical Outcomes 3.6 Epidemiology 3.7 Economic Impact

4 Competitive Assessment 4.1 Overview 4.2 Cardiac Troponins 4.3 Creatine Kinase-MB 4.4 Myoglobin 4.5 Point-of-Care

5 Unmet Needs 5.1 Overview 5.2 Earlier Diagnosis 5.3 Specificity and False Positives 5.4 Interpretation of Biochemical Assay Results 5.5 Markers for Myocardial Ischemia

6 Pipeline Products 6.1 Overview 6.2 BAG3 (Biouniversia) 6.3 CAVARISK (Cavadis) 6.4 CardioScore (BG Medicine) 6.5 Circulating Endothelial Cells 6.6 Copeptin (Thermo Scientific) 6.7 Heart-Type Fatty Acid Binding Protein 6.8 MIRISK VP Assessment (Aviir) 6.9 Early Emerging Tests

7 Industry Overview 7.1 ACS Diagnostic Biomarker Testing Trends 7.2 Market Access 7.3 Reimbursement Trends 7.4 Regulatory Environment

8 Current and Future Players 8.1 Overview 8.2 Trends in Corporate Strategy 8.3 Abbott Diagnostics 8.4 Alere 8.5 Beckman Coulter 8.6 bioMérieux 8.7 Mitsubishi (News - Alert) Chemical Medience Corporation 8.8 Ortho-Clinical Diagnostics 8.9 Radiometer Medical 8.10 Randox Laboratories 8.11 Response Biomedical 8.12 Roche Diagnostics 8.13 Siemens (News - Alert) Healthcare 8.14 Thermo Scientific

9 Market Drivers and Opportunities and Barriers

9.1 Market Drivers 9.1.1 Uptake of Pipeline Biomarker Tests 9.1.2 Increasing Adoption of POC Testing

9.2 Market Opportunities 9.2.1 High-Sensitivity Troponin Assays 9.2.2 Enhancement in Sensitivity of Troponin POC Assays 9.2.3 New Pipeline Tests for Early Diagnosis of ACS

9.3 Market Barriers 9.3.1 Saturation of Troponin Testing in the European Markets 9.3.2 Removal of CK-MB and Myoglobin from Testing Panels 9.3.3 Reimbursement

10 Country Outlooks and Forecasts

11 Appendix

For more information visit http://www.researchandmarkets.com/research/tfgdmk/medipoint

[ Back To TMCnet.com's Homepage ]